Furthermore, our study showed that IMT was increased in lower levels of CD19(+)CD5(+) and CD19(+)CD5(−) B cells, and moderate-to-severe CKD patients with lower levels of CD19(+)CD5(+) and CD19(+)CD5(−) B cells exhibited worse survival. This evidence concerns the gene CD5 and chronic kidney disease.